Identifying synthetic lethal targets using CRISPR/Cas9 system
- PMID: 28710008
- DOI: 10.1016/j.ymeth.2017.07.007
Identifying synthetic lethal targets using CRISPR/Cas9 system
Abstract
Synthetic lethality occurs when co-occurrence of two genetic events is unfavorable for the survival of the cell or organism. The conventional approach of high throughput screening of synthetic lethal targets using chemical compounds has been replaced by RNAi technology. CRISPR/Cas9, an RNA guided endonuclease system is the most recent technology for this work. Here, we have discussed the major considerations involved in designing a CRISPR/Cas9 based screening experiment for identification of synthetic lethal targets. It mainly includes CRISPR library to be used, cell types for conducting the experiment, the most appropriate screening strategy and ways of selecting the desired phenotypes from the complete cell population. The complete knockdown of genes can be achieved using CRISPR/Cas9 knockout libraries. For higher quality loss-of-function screens, haploid cells with defective homology-directed DNA repair mechanism could be used. Two widely used screening formats include arrayed and pooled screens followed by negative or positive selection of the cells with desired phenotype. However, pooled screening format with negative selection of cells serves the best. The advantages of using CRISPR/Cas9 system over the other RNAi approaches have also been discussed. Finally, some studies using CRISPR/Cas9 for genome-wide knockout screening in human cells and computational approaches for identification of synthetic lethal interactions have been discussed.
Keywords: Arrayed screen; CRISPR/Cas9; Knockout library; Pooled screen; Synthetic lethality.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Validation of Synthetic CRISPR Reagents as a Tool for Arrayed Functional Genomic Screening.PLoS One. 2016 Dec 28;11(12):e0168968. doi: 10.1371/journal.pone.0168968. eCollection 2016. PLoS One. 2016. PMID: 28030641 Free PMC article.
-
High-throughput genetic screens using CRISPR-Cas9 system.Arch Pharm Res. 2018 Sep;41(9):875-884. doi: 10.1007/s12272-018-1029-z. Epub 2018 Apr 10. Arch Pharm Res. 2018. PMID: 29637495 Review.
-
[High-throughput functional screening using CRISPR/Cas9 system].Yi Chuan. 2016 May;38(5):391-401. doi: 10.16288/j.yczz.15-329. Yi Chuan. 2016. PMID: 27232487 Review. Chinese.
-
RNAi/CRISPR Screens: from a Pool to a Valid Hit.Trends Biotechnol. 2019 Jan;37(1):38-55. doi: 10.1016/j.tibtech.2018.08.002. Epub 2018 Aug 31. Trends Biotechnol. 2019. PMID: 30177380 Review.
-
Synthetic Lethality and Cancer - Penetrance as the Major Barrier.Trends Cancer. 2018 Oct;4(10):671-683. doi: 10.1016/j.trecan.2018.08.003. Epub 2018 Sep 15. Trends Cancer. 2018. PMID: 30292351 Review.
Cited by
-
ELISL: early-late integrated synthetic lethality prediction in cancer.Bioinformatics. 2024 Jan 2;40(1):btad764. doi: 10.1093/bioinformatics/btad764. Bioinformatics. 2024. PMID: 38113447 Free PMC article.
-
Synthetic Vulnerabilities in the KRAS Pathway.Cancers (Basel). 2022 Jun 8;14(12):2837. doi: 10.3390/cancers14122837. Cancers (Basel). 2022. PMID: 35740503 Free PMC article. Review.
-
A chemical approach for global protein knockdown from mice to non-human primates.Cell Discov. 2019 Feb 5;5:10. doi: 10.1038/s41421-018-0079-1. eCollection 2019. Cell Discov. 2019. PMID: 30729032 Free PMC article.
-
Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation.Blood Adv. 2022 Apr 12;6(7):2092-2106. doi: 10.1182/bloodadvances.2021004571. Blood Adv. 2022. PMID: 34464972 Free PMC article.
-
Multi-level characteristics recognition of cancer core therapeutic targets and drug screening for a broader patient population.Front Pharmacol. 2023 Nov 23;14:1280099. doi: 10.3389/fphar.2023.1280099. eCollection 2023. Front Pharmacol. 2023. PMID: 38074121 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical